RecruitingNCT07216508

Liver Transplant CGM

Post-discharge Glycemic Control After Liver Transplant and Impact on Transplant Outcomes

Sponsor

Icahn School of Medicine at Mount Sinai

Enrollment

40 participants

Start Date

Oct 13, 2025

Study Type

OBSERVATIONAL

Conditions

Liver Transplant Type 2 Diabetes Post Transplant Diabetes

Summary

This investigator initiated study aims to describe continuous glucose monitoring (CGM) based glycemic metrics after discharge from liver transplant and assess relationship with glycemic metrics and liver transplant outcomes.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether continuous glucose monitoring (CGM) — a small sensor that tracks blood sugar around the clock — is useful for managing blood sugar levels in people recovering from a liver transplant in the hospital. **You may be eligible if...** - You have recently received a liver transplant as an inpatient - Your blood sugar has been above 180 mg/dL at least once during your hospital stay **You may NOT be eligible if...** - You are expected to be discharged to a rehabilitation facility or nursing home - You have a medical reason that prevents a CGM sensor from being placed on your skin - Your anticipated hospital stay is more than 30 days after the transplant - Your transplant also included a kidney or pancreas at the same time Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.